Wire
VYNE Approves 1-for-50 Reverse Stock Split
VYNE Therapeutics (VYNE) approved a 1-for-50 reverse stock split ahead of its planned merger with Yarrow Bioscience, the company said Tuesday.The combined company is expected to begin trading on Nasdaq as Yarrow Bioscience on July 27.VYNE also confirmed a $17.3 million special cash dividend, or about $0.402 per share, payable to eligible shareholders before the merger closes.VYNE Therapeutics stock was down over 5% during Tuesday's premarket.Price: $0.76, Change: $-0.05, Percent Change: -5.69%
$VYNE$YARW
